| Document |
Document Title |
|
WO/2018/008596A1 |
Provided is a solid phase support by which the recognition site of an antibody for detection can be oriented toward a measurement sample side so that the antibody can be immobilized in a measurement area. A solid phase support for protei...
|
|
WO/2018/005556A1 |
Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen ...
|
|
WO/2017/219974A1 |
Provided in the present invention is a bispecific antibody comprising an antibody fragment combating MUC1VHH and an antibody fragment combating CD16VHH. The antibody fragment used in the present invention is a variable region sequence de...
|
|
WO/2017/216323A2 |
The present invention relates to a method for managing the therapy of patients and patient (sub)populations (responder/non-responder) suffering from rheumatoid arthritis (RA) and to the use of suitable marker sequences, in particular in ...
|
|
WO/2017/212838A1 |
Provided is a material-fixing substrate wherein copper does not have to be used as a catalyst since a cyclic alkyne is provided at a substrate-binding region where a covalent bond is formed to a surface of the substrate, and therefore, f...
|
|
WO/2017/213107A1 |
A nanocapsule accumulation method includes: a step (C) for radiating laser light (L1) outside the wavelength region of localized surface plasmon resonance of gold nanoparticles (1) to an aqueous liquid (W) in which a plurality of nanocap...
|
|
WO/2017/206713A1 |
A method for coupling magnetic particle with antibody molecules, comprising the following steps in sequence: balancing of magnetic particles, aldehyde modification and reduction of the magnetic particles, coupling of activated magnetic p...
|
|
WO/2017/204325A1 |
[Problem] To provide: streptolysin O which has excellent properties including an antigenic activity and thermal stability; a method for producing the streptolysin O; and a use of the streptolysin O. [Solution] A polypeptide comprising su...
|
|
WO/2017/201064A1 |
This disclosure provides, e.g., methods for coupling an entity to a solid substrate. The method can comprise treating the substrate with a plasma, e.g., a CO2 plasma, to increase its reactivity. The entity can be, e.g., a biological poly...
|
|
WO/2017/201428A1 |
Provided are compositions and methods of making hydrogels, aerogels, films and composites directly from a microbial culture or complex mixture using curli nanofibers.
|
|
WO/2017/196954A1 |
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I), including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, M, m and n are as defined herein...
|
|
WO/2017/195641A1 |
The purpose of the present invention is to provide an affinity separation matrix having extremely excellent binding capacity and binding efficiency with respect to a κ-chain variable region-containing peptide, a method for producing the...
|
|
WO/2017/192801A1 |
The present invention generally relates to separation matrix comprising a lipoic acid (LA) compound or derivative thereof for use in a method for purifying and isolating a biotin-binding protein, including fusion proteins and complexes t...
|
|
WO/2017/192743A1 |
Disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified multispanning membrane polypeptide. In some instances, also disclosed herein are methods, platform, antibodies, vaccines, constr...
|
|
WO/2017/190108A1 |
The invention provides novel targeted particles as contrast agents for use in molecular imaging of vulnerable plaque, and methods of preparation and application thereof.
|
|
WO/2017/186669A1 |
The invention concerns novel streptavidin muteins and their use for determination, isolation or purification of proteins under denaturing conditons.In one embodiment such a mutein has an Cys residue at sequence position 127 of the wild-t...
|
|
WO/2017/188346A1 |
[Problem] To provide a material for efficiently capturing and collecting specific cells, and a method for capturing and collecting cells by using said material. [Solution] Provided is a material which is used for capturing and collecting...
|
|
WO/2017/180420A1 |
Provided herein are methods for determining the T cell receptor affinity and sequence of antigen-specific T cells using a micropipette adhesion assay and single cell paired TCRα/TCRβ sequencing. Further provided are methods for the tre...
|
|
WO/2017/162801A1 |
The present invention relates to the preparing of solutions, in particular for performing analysis methods, in particular by spectrometry, especially for the production of standard solutions that are useful, for example, in the calibrati...
|
|
WO/2017/165788A1 |
Disclosed are fluorescent markers that include a known number of copies of a fluorescently-labeled protein regularly interspersed along the length of the fluorescent marker. The fluorescent markers may be used to quantify fluorescently-l...
|
|
WO/2017/156616A1 |
The application relates to liposomal nanovesicles comprising porphyrin-lipid conjugates within the liposomal lipid bilayer. Said porphyrin-lipid conjugate comprise porphyrins that are modified with a -CH(R1)-O-R2 group and that chelate a...
|
|
WO/2017/157662A1 |
The invention relates to new membranes containing customised membrane transport proteins (such as TCDB-classified proteins) acting as pore-forming proteins (such as FhuA) or peptides acting as pores in the membrane. Preferably, these mem...
|
|
WO/2017/150680A1 |
This method assists in the detection of Alzheimer's disease and involves determining the profile of signal peptides contained in a bodily fluid derived from a subject being examined, and comparing said determined signal peptide profile o...
|
|
WO/2017/149002A1 |
The present invention relates to novel fusion proteins for capturing of cells. The invention features fusion proteins comprising a non-lg protein that is capable of binding a cell-surface target, at least one cleavage site for the releas...
|
|
WO/2017/083820A9 |
The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells...
|
|
WO/2017/143406A1 |
The present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes. The molecules comprise at least one binding domain molecule (BDM) which binds to a...
|
|
WO/2017/136708A1 |
A Rapafucin library containing compounds of the general structure, (A) and (E), and a synthesis of these compounds are provided.
|
|
WO/2017/103914A1 |
The present invention provides protein-polymer conjugates, and methods for generating biocompatible scaffolds formed of hydrogels comprising the conjugates and use of the scaffolds for tissue regeneration. The present invention further p...
|
|
WO/2017/094885A1 |
The present invention involves a ligand fluorescent sensor protein that specifically responds to ligands, leading to a change in fluorescence properties. The ligand fluorescent sensor protein includes a first fluorescent protein domain, ...
|
|
WO/2017/094792A1 |
The present invention relates to a targeted shell for a drug delivery system. The purpose of the present invention is to provide a targeted shell for use in a drug delivery system. Utilizing the reactivity of a thiol and an alkyl halide,...
|
|
WO/2017/088058A1 |
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected fr...
|
|
WO/2017/082942A1 |
The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the m...
|
|
WO/2017/072141A1 |
The present invention provides a system and method for assessing a synthetic peptide population including interrogating a population of peptide features in the presence of a receptor having an affinity for a binder sequence. The populati...
|
|
WO/2017/073764A1 |
The present invention addresses the problem of providing a novel NK3-receptor selective ligand which is expected to have a highly-active/highly-selective and sustained effect in vivo. A compound represented by formula (I) X1-A2-A3-X4-X5-...
|
|
WO/2017/069269A1 |
Provided is a cyclic peptide that is represented by formula (I) or formula (I'), has excellent antibody-binding characteristics, and also has improved drug stability. Also provided are an affinity chromatography support, a labeled antibo...
|
|
WO/2017/069158A1 |
The purpose of the present invention is to provide a polypeptide that has a high binding capacity to immunoglobulin kappa chains and excellent alkali stability by modifying an amino acid sequence in immunoglobulin-binding domains of prot...
|
|
WO/2017/055235A1 |
The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at ...
|
|
WO/2017/051049A1 |
The present invention relates to a peptide for treating allergies. More specifically, the invention relates to an amino acid peptide sequence (identified in the present invention as SEQ ID NO: 1) developed from various regions of Pru p 3...
|
|
WO/2017/046323A1 |
The invention relates to a peptide, comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin-binding peptide, and (iii) at least one heparin-binding peptide. The invention furthe...
|
|
WO/2017/045080A1 |
Functional three-dimensional constructs incorporating biological materials produced by additive manufacturing techniques are provided. The biological material can be a protein that is incorporated into the three-dimensional construct via...
|
|
WO/2017/042303A1 |
A first aspect of the present invention is a method of detecting antibodies comprising the steps of: i) providing a first group of beads comprising a surface modified with C1-C10 alkyl groups comprising amine, ammonium, ether and/or hydr...
|
|
WO/2017/035009A1 |
Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by...
|
|
WO/2017/029194A1 |
The present invention relates to the field of sensors, particularly to a sensor chip for detecting an anaiyte in a sample. The sensor chip comprises a substrate layer and one or more organic conjugates bound to the substrate in form of a...
|
|
WO/2017/027523A1 |
Surface-modified silica microparticles that are functionalized with stabilized phospholipid vesicles are described herein. These stabilized vesicles can be functionalized with either transmembrane receptors or membrane associated recepto...
|
|
WO/2017/026915A1 |
The invention relates to the fields of immunology and medicine and concerns the artificial construction of "core/shell"-type micro/nanoparticles containing, in the core thereof, extracts of natural allergens and/or recombinant allerge...
|
|
WO/2017/020569A1 |
Provided is a synthesis-separation purification method for an indissolvable polypeptide. An indissolvable polypeptide chain and a hydrophilic polypeptide chain are coupled by means of solid-phase synthesis, and then ester bonds are hydro...
|
|
WO/2017/023770A1 |
Embodiments of the disclosure concern methods of determining the effectiveness of immune cells, such as T cells, with particular chimeric antigen receptors. In specific embodiments, a synapse between the CAR and the tumor antigen is meas...
|
|
WO/2017/018474A1 |
The present invention pertains to a method for preparing an antibody in which the content of sugar chains having core fucose is increased, from an antibody in which sugar chains having core fucose and sugar chains not having core fucose ...
|
|
WO/2017/014261A1 |
Provided is a method for purifying an antibody-like protein, said method including a step for eluting under weakly acidic conditions. This method for purifying an antibody-like protein contains the following steps (a) and (b): (a) a step...
|
|
WO/2017/014260A1 |
The purpose of the present invention is to provide an antibody-binding protein having a reduced antibody-binding capacity in an acidic pH region. Provided is a protein containing an amino acid sequence obtained by substituting a hydropho...
|
